Freezing of Gait in Parkinson's Disease
Launched by DUKE UNIVERSITY · Jun 25, 2013
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
This study is a randomized, prospective, single-blinded six-week study in PD patients with freezing of gait (FOG).
This study will involve 2 study groups:
Group A - training group; Group B - no training group/controls.
Both groups will complete a gait evaluation and neuropsychological testing. Group A will also practice an in-home visuospatial task for 30 minutes, 4-6 days per week for six weeks. Group B will not complete the in-home tasks.
Participation in this study is expected to last 6-8 weeks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: greater than 18 years old and without an upper age limit
- • diagnosis of idiopathic PD exhibiting at least 2 or 3 cardinal signs (bradykinesia, rigidity, and resting tremor)
- • Ambulate independently without an assistive device for at least 60 meters
- • Freezing of gait episodes confirmed through the FOG-Q and evaluation by a fellowship trained Movement Disorder neurologist
- • Willingness and ability to participate in training and complete training diary
- • Documented FOG-Q and Unified Parkinson's Disease Rating Scale (UPDRS) II
- • Ability to sign informed consent
- • Pregnant females will be included in the study and there are no known risks to the pregnant female or fetus
- Exclusion Criteria:
- • Inability to complete questionnaires
- • Unwillingness to participate in training, complete all questionnaires and training diary
- • Subjects with secondary causes of parkinsonism
- • Significant dementia (MOCA \<20)
- • Prior deep brain stimulation (DBS) surgery or pallidotomy
- • Subjects cannot participate in any form of Physical Therapy, Occupational Therapy or Speech Therapy during the study period
- • Subjects cannot start any new medications during the study period.
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Mark Stacy, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials